Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
| ▸ | QPCT | Q16769 | 13/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2545178 | 0.89 | TLR8 (0.38) | EPHX1ADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL17036636 | 0.82 | ADRA2A (0.54) | EPHX1ADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL18649372 | 0.79 | ADRA2A (0.51) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL2484239 | 0.77 | EPHX1 (0.60) | EPHX1ADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL16434608 | 0.76 | QPCT (0.47) | EPHX1ADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL12257241 | 0.75 | ADRA2A (0.54) | EPHX1ADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL16434605 | 0.75 | QPCT (0.46) | EPHX1ADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL29618002 | 0.75 | P2RY14 (0.52) | EPHX1NAMPTQPCTHTTP2RY14 | |
| SCHEMBL21025210 | 0.75 | MMP12 (0.45) | EPHX1NAMPTQPCTHTT | |
| SCHEMBL2541647 | 0.75 | ADRA2A (0.50) | EPHX1ADRA2AADRA2CADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541596-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-09-24 | — | — | US | disclosed |
| EP-2560953-A2 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011131748-A2 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | WO | disclosed |
| US-20110262388-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262388-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | EPHX1 2247/4885ADRA2A 4681/4885ADRA2C 4364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.